Mission Street has appointed investor Tim Funnell to its advisory board to support expansion across core science markets in the UK.
Funnell (pictured) is a partner with Monograph Capital, a venture capital fund investing across the life sciences sector. He also serves as chief executive of Ascend, a gene therapy manufacturing business, and was a co-founder of MiroBio, which was recently acquired by pharma giant Gilead for $405m (£395m).
Funnell’s appointment comes at a time when UK life science start-ups are being constrained by the lack of labs to support growth and scale-up. Mission Street aims to correct this “market failure” through the delivery of real estate that responds to changing occupier trends and supports the full lifecycle of companies.
Artem Korolev, founder and chief executive of Mission Street, said: “All indicators point to a shortfall in lab space across the UK, but that shouldn’t mean we rush to plug that gap with inappropriate stock.
“Working directly with entrepreneurs and innovators like Tim is essential if we’re to create the right spaces for UK R&D to thrive.”
To send feedback, e-mail evelina.grecenko@eg.co.uk or tweet @Gre_Eve or @EGPropertyNews
